NCT00302003 · OUTCOME
Overall Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- Probability of survival
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- At 60 months
What was measured
Survival is defined as time from study entry to death due to any cause. Patients alive at last contact where censored at last contact.
Analysis population: Eligible (n=278). Follow-up for censored patients (n=277) is 76 months (range: 4.7 to 109 months).
Groups in this outcome
Group 1
Doxorubicin, Vincristine, Cyclophosphamide and Filgrastim
| Group | Source count |
|---|---|
| Group 1 | 278 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Group 1 | 0.99 | Not reported | 0.97 | 1.00 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 0.97
- upper Limit
- 1.00
- value
- 0.99
- denoms
- counts
- group Id
- OG000
- value
- 278
- units
- Participants
- description
- Survival is defined as time from study entry to death due to any cause. Patients alive at last contact where censored at last contact.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Doxorubicin, Vincristine, Cyclophosphamide and Filgrastim
- id
- OG000
- title
- Group 1
- param Type
- NUMBER
- population Description
- Eligible (n=278). Follow-up for censored patients (n=277) is 76 months (range: 4.7 to 109 months).
- reporting Status
- POSTED
- time Frame
- At 60 months
- title
- Overall Survival
- type
- SECONDARY
- unit Of Measure
- Probability of survival
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle